The Protein Brewery, a Dutch company specialising in fungi-derived food ingredients, has raised €30 million in a Series B funding round. The investment will support global commercial expansion, increase production capacity, and advance its proprietary mycoprotein, Fermotein®, alongside its broader innovation platform.
New investors in the round include Invest-NL and the Brabant Development Agency (BOM), joining existing backers Novo Holdings, Unovis Asset Management, and Madeli. The company plans to use the funding to strengthen sales and application support for food manufacturers, launch Fermotein® in the United States and Europe, and expand production at its Mijkenbroek facility.
Fermotein® is a high-protein, high-fibre ingredient designed for incorporation into baked goods, snacks, dairy alternatives, protein shakes, functional bars, and meal replacement products. The ingredient is tasteless and odourless, enabling versatile application. Its production leverages a proprietary fungal strain and patented process that reduces capital intensity, aiming to overcome cost and scalability challenges faced by alternative protein producers.
The Protein Brewery is targeting launches with several US customers in the coming months while preparing for EU and UK market entry pending regulatory approval. The company is also expanding operations in Singapore and continuing development of its innovation platform to explore nutritional and functional applications of Fermotein®.
The Series B funding is positioned to accelerate the company’s commercial rollout and support its role in the global transition towards sustainable protein solutions.